The transcription factor SP4 is reduced in postmortem cerebellum of bipolar disorder subjects: Control by depolarization and lithium

Bipolar Disorders

Volumn 13, Issue 5-6, 2011, Pages 474-485

  Pinacho, Raquel ^a   Villalmanzo, Nuria ^a   Lalonde, Jasmin ^b   Haro, Josep Maria ^a   Meana, J Javier ^a,c   Gill, Grace ^b,d   Ramos, Belén ^a,d  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bipolar disorder; Cerebellar granule neurons; Lithium; Postmortem cerebellum; Postmortem prefrontal cortex; SP4 SP1 transcription factor

Indexed keywords

LITHIUM; MESSENGER RNA; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP4;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; DEPOLARIZATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MALE; MENTAL DISEASE; MOOD DISORDER; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL;

ADULT; AGED; ANIMALS; ANIMALS, NEWBORN; ANTIMANIC AGENTS; BIPOLAR DISORDER; CALCIUM CHANNEL BLOCKERS; CELLS, CULTURED; CEREBELLUM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LITHIUM CHLORIDE; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NEURONS; NIMODIPINE; POSTMORTEM CHANGES; POTASSIUM CHLORIDE; PREFRONTAL CORTEX; RATS; RNA, MESSENGER; SP1 TRANSCRIPTION FACTOR; SP4 TRANSCRIPTION FACTOR; STATISTICS, NONPARAMETRIC;

EID: 80054864694     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2011.00941.x     Document Type: Article

References (68)

1. Haldane M, Frangou S. New insights help define the pathophysiology of bipolar affective disorder: neuroimaging and neuropathology findings. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 943-960.
2. Savitz J, Drevets WC. Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci Biobehav Rev 2009; 33: 699-771.
3. Hajek T, Carrey N, Alda M. Neuroanatomical abnormalities as risk factors for bipolar disorder. Bipolar Disord 2005; 7: 393-403.
4. Beyer JL, Krishnan KR. Volumetric brain imaging findings in mood disorders. Bipolar Disord 2002; 4: 89-104.
5. Bolbecker AR, Mehta C, Johannesen JK et al. Eyeblink conditioning anomalies in bipolar disorder suggest cerebellar dysfunction. Bipolar Disord 2009; 11: 19-32.
6. Schmahmann JD. An emerging concept. The cerebellar contribution to higher function. Arch Neurol 1991; 48: 1178-1187.
7. Schmahmann JD, Weilburg JB, Sherman JC. The neuropsychiatry of the cerebellum-insights from the clinic. Cerebellum 2007; 6: 254-267.
8. Schutter DJ, van Honk J. The cerebellum on the rise in human emotion. Cerebellum 2005; 4: 290-294.
9. Katz DB, Steinmetz JE. Psychological functions of the cerebellum. Behav Cogn Neurosci Rev 2002; 1: 229-241.
10. Baillieux H, De Smet HJ, Paquier PF, De Deyn PP, Mariën P. Cerebellar neurocognition: insights into the bottom of the brain. Clin Neurol Neurosurg 2008; 110: 763-773.
11. Strakowski SM, Delbello MP, Adler CM. The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings. Mol Psychiatry 2005; 10: 105-116.
12. Adler CM, DelBello MP, Jarvis K, Levine A, Adams J, Strakowski SM. Voxel-based study of structural changes in first-episode patients with bipolar disorder. Biol Psychiatry 2007; 61: 776-781.
13. Mahon K, Wu J, Malhotra AK et al. A voxel-based diffusion tensor imaging study of white matter in bipolar disorder. Neuropsychopharmacology 2009; 34: 1590-1600.
14. McQueen MB, Devlin B, Faraone SV et al. Combined analysis from eleven linkage studies of bipolar disorder provides strong evidence of susceptibility loci on chromosomes 6q and 8q. Am J Hum Genet 2005; 77: 582-595.
15. Nakatani N, Hattori E, Ohnishi T et al. Genome-wide expression analysis detects eight genes with robust alterations specific to bipolar I disorder: relevance to neuronal network perturbation. Hum Mol Genet 2006; 15: 1949-1962.
16. Ben-Shachar D, Karry R. Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. PLoS ONE 2008; 3: e3676.
17. Fatemi SH, Laurence JA, Araghi-Niknam M et al. Glial fibrillary acidic protein is reduced in cerebellum of subjects with major depression, but not schizophrenia. Schizophr Res 2004; 69: 317-323.
18. Choi KH, Elashoff M, Higgs BW et al. Putative psychosis genes in the prefrontal cortex: combined analysis of gene expression microarrays. BMC Psychiatry 2008; 8: 87.
19. Lenox RH, Hahn CG. Overview of the mechanism of action of lithium in the brain: fifty-year update. J Clin Psychiatry 2000; 61(Suppl. 9): 5-15.
20. Shastry BS. Bipolar disorder: an update. Neurochem Int 2005; 46: 273-279.
21. Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1989; 59: 411-419.
22. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-8459.
23. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996; 6: 1664-1668.
24. Mora A, Sabio G, Risco AM et al. Lithium blocks the PKB and GSK3 dephosphorylation induced by ceramide through protein phosphatase-2A. Cell Signal 2002; 14: 557-562.
25. Jorda EG, Verdaguer E, Canudas AM et al. Implication of cyclin-dependent kinase 5 in the neuroprotective properties of lithium. Neuroscience 2005; 134: 1001-1011.
26. Pardo R, Andreolotti AG, Ramos B, Picatoste F, Claro E. Opposed effects of lithium on the MEK-ERK pathway in neural cells: inhibition in astrocytes and stimulation in neurons by GSK3 independent mechanisms. J Neurochem 2003; 87: 417-426.
27. Kopnisky KL, Chalecka-Franaszek E, Gonzalez-Zulueta M, Chuang DM. Chronic lithium treatment antagonizes glutamate-induced decrease of phosphorylated CREB in neurons via reducing protein phosphatase 1 and increasing MEK activities. Neuroscience 2003; 116: 425-435.
28. Fatemi SH, Reutiman TJ, Folsom TD. The role of lithium in modulation of brain genes: relevance for aetiology and treatment of bipolar disorder. Biochem Soc Trans 2009; 37: 1090-1095.
29. Chetcuti A, Adams LJ, Mitchell PB, Schofield PR. Microarray gene expression profiling of mouse brain mRNA in a model of lithium treatment. Psychiatr Genet 2008; 18: 64-72.
30. Shi J, Potash JB, Knowles JA et al. Genome-wide association study of recurrent early-onset major depressive disorder. Mol Psychiatry 2011; 16: 193-201.
31. Shyn SI, Shi J, Kraft JB et al. Novel loci for major depression identified by genome-wide association study of sequenced treatment alternatives to relieve depression and meta-analysis of three studies. Mol Psychiatry 2011; 16: 202-215.
32. Zhou X, Tang W, Greenwood TA et al. Transcription factor SP4 is a susceptibility gene for bipolar disorder. PLoS ONE 2009; 4: e5196.
33. Tam GW, van de Lagemaat LN, Redon R et al. Confirmed rare copy number variants implicate novel genes in schizophrenia. Biochem Soc Trans 2010; 38: 445-451.
34. Zhou X, Nie Z, Roberts A et al. Reduced NMDAR1 expression in the Sp4 hypomorphic mouse may contribute to endophenotypes of human psychiatric disorders. Hum Mol Genet 2010; 19: 3797-3805.
35. Ben-Shachar D, Karry R. Sp1 expression is disrupted in schizophrenia; a possible mechanism for the abnormal expression of mitochondrial complex I genes, NDUFV1 and NDUFV2. PLoS ONE 2007; 2: e817.
36. Heintz N. Gene expression nervous system atlas (GENSAT). Nat Neurosci 2004; 7: 483.
37. Zhu H, Nguyen VT, Brown AB et al. A novel, tissue-restricted zinc finger protein (HF-1b) binds to the cardiac regulatory element (HF-1b/MEF-2) in the rat myosin light-chain 2 gene. Mol Cell Biol 1993; 13: 4432-4444.
38. Bouwman P, Philipsen S. Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol 2002; 195: 27-38.
39. Black AR, Black JD, Azizkhan-Clifford J. Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001; 188: 143-160.
40. Ramos B, Gaudilliere B, Bonni A, Gill G. Transcription factor Sp4 regulates dendritic patterning during cerebellar maturation. Proc Natl Acad Sci USA 2007; 104: 9882-9887.
41. Ramos B, Valin A, Sun X, Gill G. Sp4-dependent repression of neurotrophin-3 limits dendritic branching. Mol Cell Neurosci 2009; 42: 152-159.
42. Zhou X, Long JM, Geyer MA et al. Reduced expression of the Sp4 gene in mice causes deficits in sensorimotor gating and memory associated with hippocampal vacuolization. Mol Psychiatry 2005; 10: 393-406.
43. Vandesompele J, De Preter K, Pattyn F et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.
44. Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 2004; 64: 5245-5250.
45. Marchetti C, Usai C. High affinity block by nimodipine of the internal calcium elevation in chronically depolarized rat cerebellar granule neurons. Neurosci Lett 1996; 207: 77-80.
46. Knockaert M, Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002; 23: 417-425.
47. Guengerich FP, Sorrells JL, Schmitt S, Krauser JA, Aryal P, Meijer L. Generation of new protein kinase inhibitors utilizing cytochrome p450 mutant enzymes for indigoid synthesis. J Med Chem 2004; 47: 3236-3241.
48. Konradi C, Heckers S. Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol Psychiatry 2001; 50: 729-742.
49. Karege F, Vaudan G, Schwald M, Perroud N, La Harpe R. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res 2005; 136: 29-37.
50. Krainc D, Bai G, Okamoto S et al. Synergistic activation of the N-methyl-D-aspartate receptor subunit 1 promoter by myocyte enhancer factor 2C and Sp1. J Biol Chem 1998; 273: 26218-26224.
51. Miyatake R, Furukawa A, Suwaki H. Identification of a novel variant of the human NR2B gene promoter region and its possible association with schizophrenia. Mol Psychiatry 2002; 7: 1101-1106.
52. Zhou X, Barrett TB, Kelsoe JR. Promoter variant in the GRK3 gene associated with bipolar disorder alters gene expression. Biol Psychiatry 2008; 64: 104-110.
53. West AE, Griffith EC, Greenberg ME. Regulation of transcription factors by neuronal activity. Nat Rev Neurosci 2002; 3: 921-931.
54. Greer PL, Greenberg ME. From synapse to nucleus: calcium-dependent gene transcription in the control of synapse development and function. Neuron 2008; 59: 846-860.
55. Flavell SW, Greenberg ME. Signaling mechanisms linking neuronal activity to gene expression and plasticity of the nervous system. Annu Rev Neurosci 2008; 31: 563-590.
56. Mao X, Moerman AM, Barger SW. Neuronal kappa B-binding factors consist of Sp1-related proteins. Functional implications for autoregulation of N-methyl-D-aspartate receptor-1 expression. J Biol Chem 2002; 277: 44911-44919.
57. Hong EJ, West AE, Greenberg ME. Transcriptional control of cognitive development. Curr Opin Neurobiol 2005; 15: 21-28.
58. Song J, Mangold M, Suske G et al. Characterization and promoter analysis of the mouse gene for transcription factor Sp4. Gene 2001; 264: 19-27.
59. Andreasen NC, Nopoulos P, O'Leary DS, Miller DD, Wassink T, Flaum M. Defining the phenotype of schizophrenia: cognitive dysmetria and its neural mechanisms. Biol Psychiatry 1999; 46: 908-920.
60. Friston KJ, Frith CD. Schizophrenia: a disconnection syndrome? Clin Neurosci 1995; 3: 89-97.
61. McGuire PK, Frith CD. Disordered functional connectivity in schizophrenia. Psychol Med 1996; 26: 663-667.
62. Miguel-Hidalgo JJ, Rajkowska G. Morphological brain changes in depression: can antidepressants reverse them? CNS Drugs 2002; 16: 361-372.
63. Rosoklija G, Toomayan G, Ellis SP et al. Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders: preliminary findings. Arch Gen Psychiatry 2000; 57: 349-356.
64. Aizawa H, Hu SC, Bobb K et al. Dendrite development regulated by CREST, a calcium-regulated transcriptional activator. Science 2004; 303: 197-202.
65. Gaudilliere B, Konishi Y, de la Iglesia N, Yao G, Bonni A. A CaMKII-NeuroD signaling pathway specifies dendritic morphogenesis. Neuron 2004; 41: 229-241.
66. Redmond L, Kashani AH, Ghosh A. Calcium regulation of dendritic growth via CaM kinase IV and CREB-mediated transcription. Neuron 2002; 34: 999-1010.
67. Watase K, Gatchel JR, Sun Y et al. Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med 2007; 4: e182.
68. Zhou L, Huang KX, Kecojevic A, Welsh AM, Koliatsos VE. Evidence that serotonin reuptake modulators increase the density of serotonin innervation in the forebrain. J Neurochem 2006; 96: 396-406.